CD4 and non-small cell lung carcinoma: In phase I/II trials of patients with NSCLC, a human telomerase reverse transcriptase (hTERT)-derived helper peptide vaccine (GV1001) induced CD4+ T cells displaying a Th1 cytokine profile, and stimulated T-cell responses in >50% of subjects, without exhibiting clinically important toxicity.844,845 These results indicated a positive correlation between GV1001-specific Th1 responses and prolonged survival.